Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Iowa Icotyde Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IowaPolicy 05.06.33

    Icotyde (icotrokinra) Coverage for Plaque Psoriasis

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.06.33 alerts

    Get alerted when Policy 05.06.33 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage of Icotyde for moderate-to-severe plaque psoriasis in adults and pediatric patients age 12 years and older. It establishes preferred-product requirements, clinical approval criteria, documentation requirements, continuation criteria, and quantity limits.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyIcotyde (icotrokinra) Coverage for Plaque Psoriasis
    Policy CodePolicy 05.06.33
    Change TypeNo material change
    Effective DateSep 30, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with the required clinical documentation and meet the applicable preferred-product and approval criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsAuthorization period
    12+Minimum age
    40 kgMinimum weight
    30/30 daysQuantity limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2
    Preferred-product trials

    Coverage Criteria

    Preferred Drug Plan Design

    Initial approval under the Preferred Drug Plan Design applies when at least one applicable pathway is met.

    Adult preferred-product pathway: For adults with moderate-to-severe plaque psoriasis, meet at least one of the following: inadequate response or an intolerable adverse event with Cosentyx and another preferred product; a clinical reason to avoid Enbrel and Adalimumab-aacf plus inadequate response or an intolerable adverse event with Cosentyx and another of Otezla, Skyrizi, Otulfi (ustekinumab-aauz), or Tremfya; or current insurance-covered use of the requested product with a positive therapeutic outcome.At least one pathway

    Use obtained through samples or a manufacturer's patient assistance program does not qualify as current insurance-covered use.

    Pediatric preferred-product pathway: For pediatric moderate-to-severe plaque psoriasis, meet at least one of the following: inadequate response or an intolerable adverse event with Cosentyx and either Enbrel or Otulfi (ustekinumab-aauz); or current insurance-covered use of the requested product with a positive therapeutic outcome.At least one pathway

    Use obtained through samples or a manufacturer's patient assistance program does not qualify as current insurance-covered use.

    Initial Therapy

    Initial approval may be granted for a 12-month authorization when the member meets the applicable eligibility, clinical, and preferred-product requirements.

    Initial therapy requirements

    Continuation Therapy

    Continuation approval may be granted for a 12-month authorization when positive clinical response is achieved or maintained.

    Positive clinical response: The member has low disease activity or improvement in signs and symptoms of moderate-to-severe plaque psoriasis, demonstrated by a reduction in BSA affected from baseline or improvement from baseline in itching, redness, flaking, scaling, burning, cracking, or pain.Reduction in BSA or improvement in signs and symptoms from baseline

    Applies to all members, including new members, using Icotyde for moderate-to-severe plaque psoriasis. Approval may be subject to FDA-approved, compendia, or evidence-based dosing limits.

    Other Requirements

    The following requirements apply to all indications.

    Safety and concomitant therapy requirements

    • The member has been evaluated for tuberculosis infection before initiating treatment with a biologic or targeted synthetic drug associated with an increased risk of tuberculosis.TB evaluation before initiation when applicable
    • Icotyde is not used concomitantly with another biologic drug or targeted synthetic drug for the same indication.

    Non-Formulary Exception

    For a non-formulary exception, the approval criteria and all applicable exception requirements must be met.

    Non-formulary exception requirements

    • The requested drug is used for an FDA-approved indication or an indication supported by compendia of current literature.

      Diagnostic testing and laboratory results are required when applicable.

    • The prescribed dose and quantity fall within FDA-approved labeling or dosing guidelines in compendia of current literature.
    • All covered formulary alternatives on any tier will be ineffective, have been ineffective, would not be as effective as the non-formulary drug, or would cause adverse effects.

      Supporting documentation must address prior treatment failure, severity of any adverse event, dosage and duration of prior treatment, or contraindication to formulary alternatives.

    Concomitant therapy restriction: Icotyde must not be used with another biologic drug or targeted synthetic drug for the same indication.

    Use obtained through samples or a manufacturer's patient assistance program does not establish coverage by itself. Members receiving Icotyde through these sources must still meet the initial approval criteria.

    Icotyde is considered not medically necessary when the member does not meet the policy's stated approval criteria.

    Initial Therapy Criteria

    Moderate-to-Severe Plaque Psoriasis Initial Therapy

    Authorization may be granted for 12 months for members with moderate-to-severe plaque psoriasis who meet at least one clinical pathway.

    Member and indication

    • The member is 12 years of age or older, weighs at least 40 kg, and has moderate-to-severe plaque psoriasis for which systemic therapy or phototherapy is appropriate.Age 12 years or older; weight at least 40 kg
    • Initial clinical pathway

      • Prior biologic or targeted synthetic therapy: The member has previously received a biologic or targeted synthetic drug indicated for the treatment of moderate-to-severe plaque psoriasis.

        Examples include Sotyktu and Otezla.

      • Extent or location criteria

    Continuation Therapy Criteria

    Plaque Psoriasis Continuation

    Authorization may be granted for 12 months for all members, including new members, using Icotyde for moderate-to-severe plaque psoriasis who achieve or maintain a positive clinical response.

    Continuation response

    • The member demonstrates low disease activity or improvement in signs and symptoms through a reduction in BSA affected from baseline.Reduction in BSA from baseline
    • The member demonstrates improvement from baseline in signs or symptoms, including itching, redness, flaking, scaling, burning, cracking, or pain.Improvement in signs or symptoms from baseline

    Preferred-Product Sequencing

    RequirementExceptions
    When the requested indication is FDA-approved for the preferred products, use two preferred products before a non-preferred product.An exception applies when clinical circumstances exclude all preferred products, the member is already receiving the non-preferred drug with a positive therapeutic outcome, or only one preferred product exists for the indication.
    PopulationPreferred-product pathway
    Adults with moderate-to-severe plaque psoriasisMeet at least one pathway: inadequate response or an intolerable adverse event with Cosentyx and one additional preferred product (Adalimumab-aacf, Enbrel, Otezla, Skyrizi, Otulfi, or Tremfya); or a clinical reason to avoid Enbrel and Adalimumab-aacf plus inadequate response or an intolerable adverse event with Cosentyx and one of Otezla, Skyrizi, Otulfi, or Tremfya; or current insurance-covered use of the requested product with a positive therapeutic outcome. Samples and manufacturer patient assistance programs do not qualify as insurance-covered use.
    PopulationPreferred-product pathway
    Pediatric patients with moderate-to-severe plaque psoriasisMeet at least one pathway: inadequate response or an intolerable adverse event with Cosentyx and either Enbrel or Otulfi; or current insurance-covered use of the requested product with a positive therapeutic outcome. Samples and manufacturer patient assistance programs do not qualify as insurance-covered use.

    Quantity Limits

    Quantity Limit
    ProductIcotyde (icotrokinra) 200 mg tablet
    Standard quantity limit30 tablets per 30 days
    FDA-recommended dosing200 mg orally once daily

    Coding and Clinical Thresholds

    Procedures and Billing Codesmixed
    N/ANo specific procedure or billing codes are listed.
    Procedures and Billing Codesmixed
    No codes listed
    Crucial Body Area Involvement
    RequirementAt least one crucial body area must be affected
    ExamplesHands, feet, face, neck, scalp, genitals/groin, or intertriginous areas
    Coverage contextThis is an initial approval pathway for moderate-to-severe plaque psoriasis
    Body Surface Area
    RequirementAt least 10% of the body surface area (BSA) must be affected
    ConditionApplies to moderate-to-severe plaque psoriasis
    Authorization period

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Submission

    Submit the required documentation to initiate prior authorization review. The request must satisfy both the Preferred Drug Plan Design and the applicable initial-approval or continuation criteria.

    Prior Authorization

    Specialist Prescriber Required

    The requested medication must be prescribed by, or prescribed in consultation with, a dermatologist for plaque psoriasis.

    Step Therapy

    Preferred-Product Sequencing

    For FDA-approved indications for the preferred products, members generally must try two preferred products before a non-preferred product is considered. Exceptions may apply when clinical circumstances preclude use of all preferred products, the member is already receiving the non-preferred product with a positive therapeutic outcome, or only one preferred product is available for the indication.

    Policy Background

    Icotyde (icotrokinra) is covered for moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Coverage is determined using disease extent, involvement of crucial body areas, prior treatment response or intolerance, and clinical response during continuation therapy.

    Definitions

    Body Surface Area (BSA)
    DefinitionBSA is the body surface area affected by psoriasis
    Primary thresholdAt least 10% BSA affected
    Lower-BSA pathwayAt least 3% BSA affected plus inadequate response or intolerance to phototherapy or methotrexate, cyclosporine, or acitretin, or a clinical reason to avoid those pharmacologic treatments
    Preferred Products
    DefinitionProducts designated by the health plan for preferred utilization within the therapeutic class
    Utilization requirementGenerally use two preferred products before a non-preferred product when the requested indication is FDA-approved for the preferred products
    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyIcotyde (icotrokinra) Coverage for Plaque Psoriasis
    Policy CodePolicy 05.06.33
    Change TypeNo material change
    Effective DateSep 30, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with the required clinical documentation and meet the applicable preferred-product and approval criteria.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation Therapy CriteriaPreferred-Product SequencingQuantity LimitsCoding and Clinical ThresholdsAuthorization and Documentation RequirementsPolicy BackgroundDefinitions
  1. A crucial body area is affected.Crucial area affected

    Crucial areas include the hands, feet, face, neck, scalp, genitals/groin, and intertriginous areas.

  2. At least 10% of BSA is affected.At least 10% BSA
  3. Lower-BSA treatment pathway

    • At least 3% of BSA is affected.At least 3% BSA
    • Treatment response, intolerance, or avoidance

      • The member has had an inadequate response or intolerance to phototherapy.
      • The member has had an inadequate response or intolerance to pharmacologic treatment with methotrexate, cyclosporine, or acitretin.
      • The member has a clinical reason to avoid pharmacologic treatment with methotrexate, cyclosporine, and acitretin.

        Examples of clinical reasons to avoid these treatments are described in Appendix B.

  4. Authorization may be granted for 12 months when the criterion is met
    BSA With Prior Treatment Requirement
    BSA requirementAt least 3% of the body surface area (BSA) must be affected
    Treatment response pathwayInadequate response or intolerance to phototherapy or treatment with methotrexate, cyclosporine, or acitretin
    Treatment avoidance pathwayA clinical reason to avoid methotrexate, cyclosporine, and acitretin may also satisfy the requirement
    Minimum Patient Age
    Minimum age12 years of age and older
    Covered indicationModerate-to-severe plaque psoriasis
    Authorization periodInitial authorization may be granted for 12 months when applicable criteria are met
    Minimum Patient Weight
    Minimum weightAt least 40 kg
    Applicable patientsAdults and pediatric patients 12 years of age and older
    Treatment contextPatients must be candidates for systemic therapy or phototherapy
    • Preferred products include Adalimumab-aacf, Enbrel, Entyvio, Cosentyx, Otezla, Otulfi (ustekinumab-aauz), Rinvoq, Simponi, Skyrizi, Tremfya, Velsipity, and Xeljanz/Xeljanz XR.
    Step Therapy

    Adult Preferred-Product Trials

    For adults with moderate to severe plaque psoriasis, initial approval requires at least one applicable pathway. The member must have inadequate response or an intolerable adverse event with Cosentyx and another required preferred product, or meet the clinical-avoidance pathway; alternatively, the member may be continuing the requested product through insurance with a positive therapeutic outcome.

    • Standard pathway: inadequate response or intolerable adverse event with Cosentyx and one of Adalimumab-aacf, Enbrel, Otezla, Skyrizi, Otulfi (ustekinumab-aauz), or Tremfya.
    • Clinical-avoidance pathway: a clinical reason to avoid Enbrel and Adalimumab-aacf, plus inadequate response or intolerable adverse event with Cosentyx and one of Otezla, Skyrizi, Otulfi (ustekinumab-aauz), or Tremfya.
    • Current-therapy pathway excludes medication obtained as samples or through a manufacturer patient assistance program.
    Step Therapy

    Pediatric Preferred-Product Trials

    For pediatric members with moderate to severe plaque psoriasis, initial approval requires at least one applicable pathway. The member must have inadequate response or an intolerable adverse event with Cosentyx and another required preferred product, or be continuing the requested product through insurance with a positive therapeutic outcome.

    • Required pediatric trial products are Enbrel and Otulfi (ustekinumab-aauz), used with Cosentyx as specified in the criteria.
    • Current-therapy pathway excludes medication obtained as samples or through a manufacturer patient assistance program.
    Documentation Required

    Initial Request Documentation

    For initial requests for plaque psoriasis, submit chart notes or medical record documentation identifying the affected areas and body surface area (BSA). Also document previously tried medications, including response to therapy, or the clinical reason a therapy should be avoided.

    • Document affected area(s) and BSA.
    • Include chart notes, medical records, or claims history supporting prior medications tried and response, when applicable.
    • If a therapy was not advisable, document the clinical reason to avoid it.
    Documentation Required

    Continuation Documentation

    For continuation requests, submit chart notes or medical record documentation showing decreased BSA affected and/or improvement in signs and symptoms.

    • Document the member’s response to treatment and current clinical status.
    Documentation Required

    Non-Formulary Exception Documentation

    A non-formulary exception request must include documentation that covered formulary alternatives are ineffective, were ineffective, would not be as effective as the requested drug, or would cause adverse effects.

    • Document prior treatment failure, if applicable.
    • Describe the severity of any adverse event.
    • Include the dosage and duration of prior treatment, or document contraindication to formulary alternatives.
    Denial Risk

    Criteria Not Met

    Icotyde is considered not medically necessary when the member does not meet the applicable approval criteria. Requests that fail the required criteria may be denied.

    • The member must meet the applicable coverage criteria and have no exclusions to the prescribed therapy.
    Denial Risk

    Avoid Concurrent Biologic or Targeted Synthetic Therapy

    Do not use the requested medication concomitantly with another biologic drug or targeted synthetic drug for the same indication. The member must also have been evaluated for tuberculosis infection before initiating a biologic or targeted synthetic drug associated with increased TB risk.

    Denial Risk

    Sample or Patient Assistance Use

    Members currently receiving the requested medication as samples or through a manufacturer patient assistance program must meet the criteria for initial approval.

    • Sample or patient assistance use does not qualify as current treatment through insurance for continuation of the requested product.
    Prior Authorization

    Non-Formulary Exception Requirements

    For a non-formulary exception, the requested drug must be used for an FDA-approved indication or a compendially supported indication, and the prescribed dose or quantity must fall within FDA-approved labeling or accepted compendial dosing guidelines.

    • Provide diagnostic testing or laboratory results when applicable.
    • Meeting the standard approval criteria may satisfy some or all portions of the non-formulary exception criteria.
    • Document that all covered formulary alternatives on any tier are ineffective, were ineffective, would not be as effective, or would have adverse effects.
    Exceptions
    Exceptions may apply when clinical circumstances exclude all preferred products, the member is already receiving the non-preferred drug with a positive therapeutic outcome, or only one preferred product exists for the indication